---
title: 'Director, Value Communications at Genetix Biotherapeutics'
canonical: 'https://feeny.ai/job/director-value-communications-genetix-biotherapeutics-somerville-yxp6wwwsrt3f'
type: 'job'
last_seen: '2026-09-07'
---

# Director, Value Communications at Genetix Biotherapeutics

- **Company:** Genetix Biotherapeutics
- **Location:** Somerville, MA
- **Compensation:** $219k–$258k
- **Posted:** 2026-08-03
- **Last confirmed live:** 2026-09-07
- **Apply:** https://job-boards.greenhouse.io/genetixbiotherapeutics/jobs/8103877

## Job description

## About Genetix Biotherapeutics

At Genetix Biotherapeutics every role has meaning, every team member is respected, and every day is a chance to make a difference. When you join Genetix, you're not just landing a new role, you become part of a company that's pursuing curative gene therapies to give patients and their families more days. We are doers, thinkers and collaborators who embrace and live by our values:

Our innovation is rooted in the diversity of our teams and results are achieved through cooperation and the integration of multiple viewpoints. This is personal and we approach every challenge with radical care.

This is a full-time hybrid position (3 days a week) in our Somerville – Assembly Row, Massachusetts office.

The Director, Value Communications, is a results-driven individual responsible for shaping and executing Access Marketing strategy. This critical role ensures products are optimally positioned for coverage, reimbursement, and adoption across Payers as well as supports Qualified Treatment Center Access Marketing tools. Success in this role requires a deep understanding of the complex US healthcare landscape, including Commercial, Medicare and Medicaid as well as inpatient reimbursement pathways. This position will collaborate closely with teams across Market Access, Medical, and Marketing, as well as other cross-functional partners, to deliver integrated and impactful Access Marketing strategies, communications and training for the Field Payer Team.

- Develop and execute the US Payer, Access & Reimbursement marketing strategy for the Genetix gene therapy products through identification and analysis of key market dynamics, development of critical tactical initiatives, and long-term needs.
- Develop compelling value propositions and the payer messaging platform working cross-functionally with Medical Affairs and the Medical Value Liaison that address the unique clinical benefit and economic impact of Genetix therapies and effectively position Genetix products within the gene therapy marketplace.
- Synthesize and provide payer, access, and reimbursement strategic recommendations to executive leadership, leveraging deep understanding of the complex reimbursement landscape.
- Collaborate with cross functional partners (i.e. Field Payer Team) to gain organizational alignment and seamless execution of key payer, QTC, and reimbursement strategies.
- Oversee strategic partners to ensure execution on agreed timelines, budget, and deliverables executed in accordance with Genetix compliance and regulatory policies.
- Lead the review and approval process for access-related promotional materials and manage workflow to ensure compliance with medical, legal, and regulatory standards.
- Support the training and pull-through field-facing promotional materials with relevant field teams.
- In partnership with market access leadership, support training for Field Payer team including new hires, continuing education, and national meetings.
- Manage Value Communications budget

## Qualifications

Experience:

- 8+ years of experience in Payer/Access Marketing, Market Access Strategy, Field Market Access/HEOR Training and/or Value Communications within the pharmaceutical, biotech, or consulting industry.
- Bachelor’s degree required (preferred fields: Business, Marketing, Communications).  Relevant advanced degree a plus.
- Possesses recent experience in the successful commercialization of specialty therapies, preferably in the rare disease or Cell and Gene Therapy space.
- Demonstrated history of successful collaboration with cross-functional teams.
- Extensive experience in shaping market access strategies, developing brand plans and payer marketing tools (such as value proposition decks), informing HEOR data strategies, and supporting field market access teams.
- Previous experience supporting Specialty Distribution and Specialty Pharmacy products.
- Experience with MLR/PRC and Veeva.
- Experience developing and managing promotional budgets and overseeing third-party vendors.
- Knowledge of market and competitive environment.

Skills & Competencies:

- Strong sense of urgency, accountability, and patient-centric focus.
- Excellent verbal and written communication with high emotional intelligence and active listening.
- Strong quantitative and qualitative analytical, investigative, and critical thinking skills with ability to translate insights into action.
- Ability to work independently and manage multiple projects with initiative, including project planning and prioritizing competing demands.
- Proven ability to establish and sustain trusted relationships with internal partners and to work effectively in teams.
- Excellent written, verbal, and presentation communication skills, strong interpersonal influencing and prioritization abilities, and proven capacity to influence within matrixed organizations, including influencing without authority.
- Creative problem-solving abilities, strategic vision, and the ability to explore innovative approaches in an evolving landscape.
- Ability to quickly forge strong partnerships with both internal and external partners.
- Strategic thinking combined with the ability to execute to achieve operational excellence in the face of challenging goals.
- Ability to work independently and manage a high volume of complex, ongoing responsibilities
- Proficiency in Microsoft Excel, Word, PowerPoint, and data entry systems.

Other Requirements:

- Ability to work effectively in a fast-paced, evolving environment with competing priorities.
- Ability to travel up to 40%.

Additional Information

The pay transparency range provided below is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. We may ultimately pay more or less than the posted range, and the range may be modified in the future. This role is eligible for an annual bonus and long-term incentive. Actual base salary pay will be based on several factors, including but not limited to experience, skills, relevant education/qualifications, external market, internal equity, and other job-related factors permitted by law.

Genetix’s total rewards package also provides employees with a comprehensive and competitive benefits suite to support a variety of employee needs. These benefits include comprehensive health, life and disability insurance, employer-matched 401(k) plan, lifestyle spending account, flexible time-off + paid holidays and winter holiday period, tuition reimbursement & loan repayment assistance, paid parental leave, paid onsite parking, commuter subsidy, and much more.

Pay Transparency $219,000—$258,000 USD

Genetix is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, veteran status or any other applicable legally protected characteristics.

## About Genetix Biotherapeutics

## Company Overview
- **One-liner**: Genetix Biotherapeutics (formerly bluebird bio) is a commercial-stage biotechnology company dedicated to developing and delivering one-time, curative genetic therapies for patients with severe rare genetic diseases.
- **Entity Type**: Private (taken private in June 2025 after a sale to new ownership)
- **Headquarters**: Somerville, Massachusetts, USA (with a presence in the Netherlands)
- **Founded**: 1992 (founded as Genetix Pharmaceuticals; rebranded to bluebird bio in 2010; rebranded back to Genetix Biotherapeutics in September 2025)
- **Founders**: Not publicly disclosed; the company was originally founded as Genetix Pharmaceuticals in 1992.

## Core Business
- **Primary Industries**: Biotechnology, Gene Therapy, Rare Disease Therapeutics
- **Target Customers**: B2B (healthcare providers, qualified treatment centers, payers/insurers) and B2C (patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy)
- **Mission**: "To transform lives through curative therapies for patients with rare, genetic diseases."

## Products & Services
- **LYFGENIA™ (lovotibeglogene autotemcel / lovo-cel)**: An FDA-approved, one-time gene therapy for patients 12 years and older with sickle cell disease. It works by adding functional copies of a modified β-globin gene into the patient's own blood stem cells.
- **ZYNTEGLO™ (betibeglogene autotemcel)**: An FDA-approved, one-time gene therapy for patients with β-thalassemia who require regular blood transfusions. It adds functional copies of a modified β-globin gene into the patient's own blood stem cells.
- **SKYSONA™ (elivaldogene autotemcel)**: An FDA-approved, one-time gene therapy for boys with cerebral adrenoleukodystrophy (CALD), a rare, progressive genetic brain disease. It adds a functional copy of the ABCD1 gene into the patient's own blood stem cells.
- **Patient Support Program**: Personalized assistance for patients and families navigating the treatment journey, including insurance questions, treatment center coordination, and one-on-one support.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (privately held after take-private transaction in June 2025)
- **Key Metrics**:
  - **Annual Revenue**: Not publicly disclosed (but the company reported strong revenue growth in 2025 and achieved its **first ever profitable quarter** in that year)
  - **Total Funding**: Not publicly disclosed (new investors provided "significant capital" to support operational objectives following the take-private transaction)
- **Notable Investors/Partners**: New ownership group (undisclosed); manufacturing partners include **Minaris**, **Lonza**, and **MilliporeSigma** (the U.S. and Canada business of Merck KGaA, Darmstadt, Germany)
- **Growth Signals**:
  - **2025 commercial performance**: >100 patients treated in the U.S.; >150 patients completed their first cell collection cycle; 70 active Qualified Treatment Centers (QTCs) — the largest network for hemoglobinopathy gene therapies nationwide
  - **2026 outlook**: Doubling manufacturing capacity by mid-2026; targeting first full year of profitability; expanding LYFGENIA label to pediatric patients <12 years of age; advancing cryopreserved apheresis to improve the treatment experience

## Competitive Advantages
- **First-mover & market leader**: The only company with FDA approval for three gene therapies, and the market leader in the U.S. for hemoglobinopathy gene therapies
- **Proven commercial model**: >100 patients treated in a single year demonstrates real-world commercial execution and manufacturing scale
- **Decades of scientific innovation**: Over 30 years of R&D in genetic therapy, with extensive clinical data from hundreds of treated patients (including 15-year long-term follow-up studies)
- **Strong access**: LYFGENIA and ZYNTEGLO have meaningful access for >90% of eligible patients with commercial or Medicaid coverage
- **One-time curative approach**: Therapies are designed to treat the underlying cause of disease, offering durable, potentially life-long benefits from a single administration

## Strategic Focus
- **Commercial execution & patient access**: Expanding the Qualified Treatment Center network and making the treatment journey simpler for patients and providers
- **Manufacturing scale-up**: Doubling manufacturing capacity in 2026 through partnerships with CDMOs to meet growing patient demand
- **Process optimization**: Implementing cryopreserved apheresis to improve the patient and provider experience
- **Label expansion**: Advancing the HGB-210 Phase 3 study to bring LYFGENIA to pediatric sickle cell patients under 12 years of age
- **Full-year profitability**: Targeting the company's first full year of profitability in 2026

## Why Work Here
- **Mission-driven culture**: "United by purpose" — the company is laser-focused on transforming the lives of patients with rare, genetic diseases through curative therapies
- **Strong momentum**: Recently achieved first-ever profitable quarter, with rapid commercial growth and a clear plan for expansion in 2026
- **Remote/hybrid policy**: Roles are listed as both on-site (Somerville, MA) and remote (e.g., Account Manager, Gene Therapy) — flexible arrangements appear available depending on the role
- **Active hiring**: 23 job postings as of the search date, spanning Commercial, Quality Assurance, Technical Operations, Medical, and Regulatory functions
- **Experienced leadership**: Led by CEO David Meek (ex-Mirati Therapeutics, Ipsen) with a seasoned executive team of industry veterans, signaling strong strategic direction
- **Notable perks/culture**: High-impact work at the intersection of cutting-edge science and commercial execution; opportunity to join a company in the middle of a dramatic turnaround and growth phase; patient-centric focus with a dedicated support program

## Sources
1. [genetixbiotx.com - Company website](https://www.genetixbiotx.com/)
2. [job-boards.greenhouse.io - Careers page](http://job-boards.greenhouse.io/genetixbiotherapeutics)
3. [linkedin.com - LinkedIn company page](https://www.linkedin.com/company/genetix-biotherapeutics)
4. [genetixbiotx.com - Press release: Rebrand from bluebird bio](https://www.genetixbiotx.com/press-release-2025-09-18.html)
5. [genetixbiotx.com - Press release: 2025 commercial results & 2026 priorities](https://www.genetixbiotx.com/press-release-2026-03-02.html)

## Other roles at Genetix Biotherapeutics

- [Sr. Manager - IT Commercial and Medical Systems](https://feeny.ai/job/sr-manager-it-commercial-and-medical-systems-genetix-biotherapeutics-somerville-drs30kf4perv) — Somerville, MA
- [Sr. Director, Regulatory Strategy](https://feeny.ai/job/sr-director-regulatory-strategy-genetix-biotherapeutics-somerville-fpj4qjceza7s) — Somerville, MA
- [Manager, End User Services & Lab Support](https://feeny.ai/job/manager-end-user-services-lab-support-genetix-biotherapeutics-somerville-q2ah951d4k1c) — Somerville, MA
- [Director, Regulatory Advertising and Promotion](https://feeny.ai/job/director-regulatory-advertising-and-promotion-genetix-biotherapeutics-somerville-4ykm3383hgsq) — Somerville, MA
- [Regional Medical Director, Gene Therapy](https://feeny.ai/job/regional-medical-director-gene-therapy-genetix-biotherapeutics-remote-wz9vc7s3xy0n)
- [Paralegal and Legal & Compliance Operations Manager](https://feeny.ai/job/paralegal-and-legal-compliance-operations-manager-genetix-biotherapeutics-m768zfn33tct) — Somerville, MA
- [Associate Manager, Quality Assurance Operations](https://feeny.ai/job/associate-manager-quality-assurance-operations-genetix-biotherapeutics-8m008cez8h16) — Somerville, MA
- [Sr. Manager, Quality Assurance for Quality Control](https://feeny.ai/job/sr-manager-quality-assurance-for-quality-control-genetix-biotherapeutics-j6a4xrp93mf0) — Somerville, MA
- [Account Manager, Gene Therapy - Pacific Northwest](https://feeny.ai/job/account-manager-gene-therapy-pacific-northwest-genetix-biotherapeutics-seattle-cdgars1xqtra) — Seattle, WA
- [Director of Scientific Communications & Evidence Generation](https://feeny.ai/job/director-of-scientific-communications-evidence-generation-genetix-ddek20fjzkgt) — Somerville, MA